Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocytes (43 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 7 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14102
Sealed predictions
- GPS2 in dopamine neurons, braakn/a → n/areceipt 14109
- GPS2 in oligodendrocytes, braak+0.03 (p 0.944) → +0.52 (p 0.152)receipt 14108
Swarm cases
receipt 14109: GPS2 in dopamine neurons, braak
- cell type
- GPS2 is not measured in dopamine neurons; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GPS2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 14108: GPS2 in oligodendrocytes, braak
- power
- full sample +0.26 (p 0.298, n 18), 95% CI -0.24 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.28 (p 0.269, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.40 (p 0.101, n 18). could be the mix.
- skeptic
- leave-one-out range +0.16 to +0.34, sign flips 0; without severely affected donors +0.26 (p 0.298, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GPS2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts